Evaluation of the exit screening policy among travelers arriving from Asian and pacific nations

• Published in: BMC infectious diseases 2024-05, Vol.24 (1), p.464-464, Article 464
• Main Authors: Liu, Shiqi, Anzai, Asami, Nishiura, Hiroshi
• Format: Article
• Language: English
• Subjects: Analysis; Antigens; Asia; Border control; Border patrols; Border stations; Boundaries; Control; Coronaviruses; COVID-19; COVID-19 - diagnosis; COVID-19 - epidemiology; COVID-19 - prevention & control; Datasets; Disease transmission; Effectiveness; Epidemics; Epidemiology; Estimates; Evaluation; Health aspects; Health risks; Humans; Incidence; Income; Infections; Japan; Japan - epidemiology; Laws, regulations and rules; Mass Screening; Medical policy; Medical research; Medical screening; Medicine, Experimental; Nations; Noncitizens; Performance evaluation; Quality assurance; Quarantine; Risk assessment; Risk management; SARS-CoV-2 - isolation & purification; Screening; Severe acute respiratory syndrome; Severe acute respiratory syndrome coronavirus 2; Standardization; Statistical estimation; Travel; Travelers
• ISSN: 1471-2334; 1471-2334
• DOI: 10.1186/s12879-024-09327-8

The Japanese government has instituted border control measures against COVID-19, including entry and exit screening of people arriving from overseas. We sought to evaluate the effectiveness of the exit screening policy in Japan in reducing the risk of importing COVID-19 cases among travelers from Asian and Pacific countries. The study period was stratified based on the timing of exit screening: (i) the control period (the pre-exit screening period from 25 October 2020 to 16 January 2021), (ii) the time period with the Alpha variant from 17 January to 10 April 2021, and (iii) the time period with the Delta variant from 2 May to 2 October 2021. Incidence data in the countries of origin were used to adjust for the risk of infection among travelers. The positivity rate of entry screening in Japan was compared among the three different study periods, adjusting for the risk of infection in the country of origin. The adjusted relative risk of positivity was greatly reduced and substantially below the value of 1 during the Alpha variant period compared with the control period. Although the relative risks increased when comparing the Delta variant period against control, the estimate remained below 1, except for among travelers from India and Myanmar. The relative risk reduction was greatest in high-income countries, with estimates of 100% and 96% risk reduction during the Alpha and Delta variant periods, respectively, followed by upper-middle-income countries with estimates of 90% and 76%, respectively. Even in the presence of the Alpha and Delta variants, exit screening clearly reduced the risk of infection among travelers arriving from Asian and Pacific nations. As the testing relies on the country of origin, the effectiveness varied greatly by the socioeconomic income status and epidemiological situation of those countries. Test standardization and quality assurance may be required in low- and middle-income countries.